STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G

NAMS Schedule 13G filing by Fidelity / FMR

Fidelity / FMR reported beneficial ownership of 6.4M shares, representing 12% of NewAmsterdam Pharma Co N.V. in this filing.

FiledFeb 5, 2026
Ownership dateDec 31, 2025
Reported shares6.4M
Reported ownership12%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 6.4M
Shared voting power 6.4M
Sole dispositive power 6.4M
Shared dispositive power 6.4M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$32.06as of Feb 5, 2026
Latest tracked price$27.42as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
Fidelity / FMR
CIK
CIK0000315066
Accession
0000315066-26-000486
Form
Schedule 13G
Open SEC filing View NAMS ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →